You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Claims for Patent: 7,087,224

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,087,224

Title:	Method of treating anemia by administering IL-1ra
Abstract:	The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.
Inventor(s):	Kay; Jonathan (Newton Centre, ME), McCabe; Dorothy (Moorpark, CA), Newmark; Richard (Newbury Park, CA), Coccia; Marco A. (Camarillo, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	09/969,739
Patent Claims:	1. A method of raising hematocrit in a mammal, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising anakinra. 2. The method of claim 1, wherein the hematocrit target is at least about 30%. 3. The method of claim 1, wherein the pharmaceutical composition comprises at least one of a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative, and adjuvant. 4. The method of claim 3, wherein the diluent is a buffer solution of sodium citrate or sodium phosphate. 5. The method of claim 3, wherein the diluent is a buffer solution of sodium citrate. 6. The method of claim 3, wherein the solubilizer is polysorbate 80. 7. The method of claim 3, wherein the pharmaceutical composition comprises a pharmaceutically acceptable diluent and solubilizer. 8. The method of claim 7, wherein the diluent is sodium citrate and the solubilizer is polysorbate 80. 9. The method of claim 1, wherein the mammal has anemia associated with a decline or loss of kidney function. 10. The method of claim 1, wherein the mammal has anemia associated with rheumatoid arthritis. 11. The method of claim 1, wherein the mammal has anemia associated with myelosuppressive therapy. 12. The method of claim 11, wherein the myelosuppressive therapy comprises chemotherapeutic or anti-viral drugs. 13. The method of claim 1, wherein the mammal has anemia associated with excessive blood loss. 14. The method of claim 1, which further comprises administering a therapeutically effective amount of iron.

Details for Patent 7,087,224

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	KINERET	anakinra	Injection	103950	11/14/2001	⤷ Try a Trial	2020-10-31
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.